<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d288">
    <sentence id="DDI-DrugBank.d288.s0" text="In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).">
        <entity charOffset="45-49" id="DDI-DrugBank.d288.s0.e0" text="TAXOL" type="brand"/>
        <entity charOffset="71-79" id="DDI-DrugBank.d288.s0.e1" text="cisplatin" type="drug"/>
        <entity charOffset="169-173" id="DDI-DrugBank.d288.s0.e2" text="TAXOL" type="brand"/>
        <entity charOffset="191-199" id="DDI-DrugBank.d288.s0.e3" text="cisplatin" type="drug"/>
        <entity charOffset="239-243" id="DDI-DrugBank.d288.s0.e4" text="TAXOL" type="brand"/>
        <entity charOffset="252-260" id="DDI-DrugBank.d288.s0.e5" text="cisplatin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e0" e2="DDI-DrugBank.d288.s0.e1" id="DDI-DrugBank.d288.s0.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e0" e2="DDI-DrugBank.d288.s0.e2" id="DDI-DrugBank.d288.s0.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e0" e2="DDI-DrugBank.d288.s0.e3" id="DDI-DrugBank.d288.s0.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e0" e2="DDI-DrugBank.d288.s0.e4" id="DDI-DrugBank.d288.s0.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e0" e2="DDI-DrugBank.d288.s0.e5" id="DDI-DrugBank.d288.s0.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e1" e2="DDI-DrugBank.d288.s0.e2" id="DDI-DrugBank.d288.s0.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e1" e2="DDI-DrugBank.d288.s0.e3" id="DDI-DrugBank.d288.s0.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e1" e2="DDI-DrugBank.d288.s0.e4" id="DDI-DrugBank.d288.s0.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e1" e2="DDI-DrugBank.d288.s0.e5" id="DDI-DrugBank.d288.s0.p8"/>
        <pair ddi="true" e1="DDI-DrugBank.d288.s0.e2" e2="DDI-DrugBank.d288.s0.e3" id="DDI-DrugBank.d288.s0.p9" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e2" e2="DDI-DrugBank.d288.s0.e4" id="DDI-DrugBank.d288.s0.p10"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e2" e2="DDI-DrugBank.d288.s0.e5" id="DDI-DrugBank.d288.s0.p11"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e3" e2="DDI-DrugBank.d288.s0.e4" id="DDI-DrugBank.d288.s0.p12"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e3" e2="DDI-DrugBank.d288.s0.e5" id="DDI-DrugBank.d288.s0.p13"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s0.e4" e2="DDI-DrugBank.d288.s0.e5" id="DDI-DrugBank.d288.s0.p14"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s1" text="Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.">
        <entity charOffset="68-77" id="DDI-DrugBank.d288.s1.e0" text="paclitaxel" type="drug"/>
        <entity charOffset="115-119" id="DDI-DrugBank.d288.s1.e1" text="TAXOL" type="brand"/>
        <entity charOffset="148-156" id="DDI-DrugBank.d288.s1.e2" text="cisplatin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s1.e0" e2="DDI-DrugBank.d288.s1.e1" id="DDI-DrugBank.d288.s1.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s1.e0" e2="DDI-DrugBank.d288.s1.e2" id="DDI-DrugBank.d288.s1.p1"/>
        <pair ddi="true" e1="DDI-DrugBank.d288.s1.e1" e2="DDI-DrugBank.d288.s1.e2" id="DDI-DrugBank.d288.s1.p2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s2" text="The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4.">
        <entity charOffset="18-22" id="DDI-DrugBank.d288.s2.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s3" text="In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4.">
        <entity charOffset="107-111" id="DDI-DrugBank.d288.s3.e0" text="TAXOL" type="brand"/>
    <negationtags>In the &lt;scope&gt; &lt;cue&gt; absence of &lt;/cue&gt; formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d288.s4" text="Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.">
        <entity charOffset="31-35" id="DDI-DrugBank.d288.s4.e0" text="TAXOL" type="brand"/>
        <entity charOffset="65-83" id="DDI-DrugBank.d288.s4.e1" text="protease inhibitors" type="group"/>
        <entity charOffset="86-94" id="DDI-DrugBank.d288.s4.e2" text="ritonavir" type="drug"/>
        <entity charOffset="97-106" id="DDI-DrugBank.d288.s4.e3" text="saquinavir" type="drug"/>
        <entity charOffset="109-117" id="DDI-DrugBank.d288.s4.e4" text="indinavir" type="drug"/>
        <entity charOffset="124-133" id="DDI-DrugBank.d288.s4.e5" text="nelfinavir" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e0" e2="DDI-DrugBank.d288.s4.e1" id="DDI-DrugBank.d288.s4.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e0" e2="DDI-DrugBank.d288.s4.e2" id="DDI-DrugBank.d288.s4.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e0" e2="DDI-DrugBank.d288.s4.e3" id="DDI-DrugBank.d288.s4.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e0" e2="DDI-DrugBank.d288.s4.e4" id="DDI-DrugBank.d288.s4.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e0" e2="DDI-DrugBank.d288.s4.e5" id="DDI-DrugBank.d288.s4.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e1" e2="DDI-DrugBank.d288.s4.e2" id="DDI-DrugBank.d288.s4.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e1" e2="DDI-DrugBank.d288.s4.e3" id="DDI-DrugBank.d288.s4.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e1" e2="DDI-DrugBank.d288.s4.e4" id="DDI-DrugBank.d288.s4.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e1" e2="DDI-DrugBank.d288.s4.e5" id="DDI-DrugBank.d288.s4.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e2" e2="DDI-DrugBank.d288.s4.e3" id="DDI-DrugBank.d288.s4.p9"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e2" e2="DDI-DrugBank.d288.s4.e4" id="DDI-DrugBank.d288.s4.p10"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e2" e2="DDI-DrugBank.d288.s4.e5" id="DDI-DrugBank.d288.s4.p11"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e3" e2="DDI-DrugBank.d288.s4.e4" id="DDI-DrugBank.d288.s4.p12"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e3" e2="DDI-DrugBank.d288.s4.e5" id="DDI-DrugBank.d288.s4.p13"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s4.e4" e2="DDI-DrugBank.d288.s4.e5" id="DDI-DrugBank.d288.s4.p14"/>
    <negationtags>Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; been evaluated in clinical trials. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d288.s5" text="Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.">
        <entity charOffset="56-66" id="DDI-DrugBank.d288.s5.e0" text="doxorubicin" type="drug"/>
        <entity charOffset="95-107" id="DDI-DrugBank.d288.s5.e1" text="doxorubicinol" type="drug_n"/>
        <entity charOffset="132-141" id="DDI-DrugBank.d288.s5.e2" text="paclitaxel" type="drug"/>
        <entity charOffset="147-157" id="DDI-DrugBank.d288.s5.e3" text="doxorubicin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s5.e0" e2="DDI-DrugBank.d288.s5.e1" id="DDI-DrugBank.d288.s5.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s5.e0" e2="DDI-DrugBank.d288.s5.e2" id="DDI-DrugBank.d288.s5.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s5.e0" e2="DDI-DrugBank.d288.s5.e3" id="DDI-DrugBank.d288.s5.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s5.e1" e2="DDI-DrugBank.d288.s5.e2" id="DDI-DrugBank.d288.s5.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s5.e1" e2="DDI-DrugBank.d288.s5.e3" id="DDI-DrugBank.d288.s5.p4"/>
        <pair ddi="true" e1="DDI-DrugBank.d288.s5.e2" e2="DDI-DrugBank.d288.s5.e3" id="DDI-DrugBank.d288.s5.p5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s6" text="Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3.">
        <entity charOffset="12-16" id="DDI-DrugBank.d288.s6.e0" text="TAXOL" type="brand"/>
    <negationtags>Hematology: TAXOL therapy should &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d288.s7" text="In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL.">
        <entity charOffset="153-157" id="DDI-DrugBank.d288.s7.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s8" text="Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level  1500 cells/mm3 and platelets recover to a level  100,000 cells/mm3.">
        <entity charOffset="60-64" id="DDI-DrugBank.d288.s8.e0" text="TAXOL" type="brand"/>
    <negationtags>Patients should &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level 1500 cells/mm3 and platelets recover to a level 100,000 cells/mm3. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d288.s9" text="In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended.">
        <entity charOffset="93-97" id="DDI-DrugBank.d288.s9.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s10" text="For patients with advanced HIV disease and poor-risk AIDS-related Kaposi s sarcoma, TAXOL, at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3.">
        <entity charOffset="84-88" id="DDI-DrugBank.d288.s10.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s11" text="Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.">
        <entity charOffset="131-141" id="DDI-DrugBank.d288.s11.e0" text="cyclosporin" type="drug"/>
        <entity charOffset="173-182" id="DDI-DrugBank.d288.s11.e1" text="teniposide" type="drug"/>
        <entity charOffset="238-242" id="DDI-DrugBank.d288.s11.e2" text="TAXOL" type="brand"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s11.e0" e2="DDI-DrugBank.d288.s11.e1" id="DDI-DrugBank.d288.s11.p0"/>
        <pair ddi="true" e1="DDI-DrugBank.d288.s11.e0" e2="DDI-DrugBank.d288.s11.e2" id="DDI-DrugBank.d288.s11.p1" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d288.s11.e1" e2="DDI-DrugBank.d288.s11.e2" id="DDI-DrugBank.d288.s11.p2" type="advise"/>
    <negationtags>Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; be treated with TAXOL. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d288.s12" text="In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).">
        <entity charOffset="97-101" id="DDI-DrugBank.d288.s12.e0" text="TAXOL" type="brand"/>
        <entity charOffset="131-145" id="DDI-DrugBank.d288.s12.e1" text="corticosteroids" type="group"/>
        <entity charOffset="156-168" id="DDI-DrugBank.d288.s12.e2" text="dexamethasone" type="drug"/>
        <entity charOffset="193-206" id="DDI-DrugBank.d288.s12.e3" text="H2 antagonists" type="group"/>
        <entity charOffset="217-226" id="DDI-DrugBank.d288.s12.e4" text="cimetidine" type="drug"/>
        <entity charOffset="231-240" id="DDI-DrugBank.d288.s12.e5" text="ranitidine" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e0" e2="DDI-DrugBank.d288.s12.e1" id="DDI-DrugBank.d288.s12.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e0" e2="DDI-DrugBank.d288.s12.e2" id="DDI-DrugBank.d288.s12.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e0" e2="DDI-DrugBank.d288.s12.e3" id="DDI-DrugBank.d288.s12.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e0" e2="DDI-DrugBank.d288.s12.e4" id="DDI-DrugBank.d288.s12.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e0" e2="DDI-DrugBank.d288.s12.e5" id="DDI-DrugBank.d288.s12.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e1" e2="DDI-DrugBank.d288.s12.e2" id="DDI-DrugBank.d288.s12.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e1" e2="DDI-DrugBank.d288.s12.e3" id="DDI-DrugBank.d288.s12.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e1" e2="DDI-DrugBank.d288.s12.e4" id="DDI-DrugBank.d288.s12.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e1" e2="DDI-DrugBank.d288.s12.e5" id="DDI-DrugBank.d288.s12.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e2" e2="DDI-DrugBank.d288.s12.e3" id="DDI-DrugBank.d288.s12.p9"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e2" e2="DDI-DrugBank.d288.s12.e4" id="DDI-DrugBank.d288.s12.p10"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e2" e2="DDI-DrugBank.d288.s12.e5" id="DDI-DrugBank.d288.s12.p11"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e3" e2="DDI-DrugBank.d288.s12.e4" id="DDI-DrugBank.d288.s12.p12"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e3" e2="DDI-DrugBank.d288.s12.e5" id="DDI-DrugBank.d288.s12.p13"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s12.e4" e2="DDI-DrugBank.d288.s12.e5" id="DDI-DrugBank.d288.s12.p14"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s13" text="Minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia do not require interruption of therapy."><negationtags>Minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia do &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; require interruption of therapy. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d288.s14" text="However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.">
        <entity charOffset="86-100" id="DDI-DrugBank.d288.s14.e0" text="bronchodilators" type="group"/>
        <entity charOffset="177-181" id="DDI-DrugBank.d288.s14.e1" text="TAXOL" type="brand"/>
        <pair ddi="false" e1="DDI-DrugBank.d288.s14.e0" e2="DDI-DrugBank.d288.s14.e1" id="DDI-DrugBank.d288.s14.p0"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s15" text="Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL.">
        <entity charOffset="94-98" id="DDI-DrugBank.d288.s15.e0" text="TAXOL" type="brand"/>
    <negationtags>Patients who have developed severe hypersensitivity reactions should &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; be rechallenged with TAXOL. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d288.s16" text="Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL, but generally do not require treatment.">
        <entity charOffset="103-107" id="DDI-DrugBank.d288.s16.e0" text="TAXOL" type="brand"/>
    <negationtags>Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL, but generally do &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; require treatment. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d288.s17" text="Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension.">
        <entity charOffset="13-17" id="DDI-DrugBank.d288.s17.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s18" text="Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended.">
        <entity charOffset="70-74" id="DDI-DrugBank.d288.s18.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s19" text="Continuous cardiac monitoring is not required except for patients with serious conduction abnormalities."><negationtags>Continuous cardiac monitoring is &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; required &lt;/scope&gt; except for patients with serious conduction abnormalities.</negationtags></sentence>
    <sentence id="DDI-DrugBank.d288.s20" text="Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL.">
        <entity charOffset="196-200" id="DDI-DrugBank.d288.s20.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s21" text="TAXOL contains dehydrated alcohol USP, 396 mg/mL;">
        <entity charOffset="0-4" id="DDI-DrugBank.d288.s21.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s22" text="consideration should be given to possible CNS and other effects of alcohol.">
        <entity charOffset="67-73" id="DDI-DrugBank.d288.s22.e0" text="alcohol" type="drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s23" text="Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin  2 times ULN.">
        <entity charOffset="61-65" id="DDI-DrugBank.d288.s23.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s24" text="Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17.">
        <entity charOffset="55-59" id="DDI-DrugBank.d288.s24.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s25" text="InjectionSite Reaction: Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site."/>
    <sentence id="DDI-DrugBank.d288.s26" text="These reactions have been observed more frequently with the 24-hour infusion than with the 3-hour infusion."/>
    <sentence id="DDI-DrugBank.d288.s27" text="Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely.">
        <entity charOffset="93-97" id="DDI-DrugBank.d288.s27.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s28" text="Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety.">
        <entity charOffset="180-184" id="DDI-DrugBank.d288.s28.e0" text="TAXOL" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s29" text="In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days."/>
    <sentence id="DDI-DrugBank.d288.s30" text="A specific treatment for extravasation reactions is unknown at this time."/>
    <sentence id="DDI-DrugBank.d288.s31" text="Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration."/>
</document>